Nuformix PLC (NFXN)

London

Currency in GBP

Disclaimer

0.2800

-0.0150(-5.26%)

Closed22/09

Day's Range

0.2570

0.3000

52 wk Range

0.2000

0.5500

Unusual trading volume

Day's Range

0.25700.3000

52 wk Range

0.20000.5500

Prev. Close: 0.285
Open: 0.27
Day's Range: 0.257-0.3
52 wk Range: 0.2-0.55
Volume: 7,135,532
Average Volume (3m): 2,760,652
1-Year Change: -30%
Shares Outstanding: 744,309,368

Market Cap: 2.08M
Revenue: -
P/E Ratio: -2.80
EPS: -0.001
Dividend (Yield): N/A
(N/A)
Beta: 0.463
Next Earnings Date: -
ISIN: GB00BYW79Y38

Technical

Strong Sell

Sell

Neutral

Buy

Strong Buy

Strong Sell

Daily

Weekly

Monthly

Explore

Nuformix PLC News

Nuformix delighted as NXP004 testing exceeds the company’s expectations
- ByProactive Investors
- •20 Dec 2022
Proactive Investors - Nuformix PLC has updated investors on its NXP004 programme which is developing novel forms of AstraZeneca’s Olaparib (Lynparza®) cancer...

Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy-induced nausea and vomiting). NXP004 is a form of Olaparib, which is used for the treatment of several cancers.

Industry

Pharmaceuticals

Sector

Healthcare

Employees

Market

United Kingdom

Income Statement

Markets

FTSE 100

7,683.91

+5.29

+0.07%

DAX

15,557.29

-14.57

-0.09%

Euro Stoxx 50

4,207.55

-5.04

-0.12%

S&P 500

4,320.06

-9.94

-0.23%

Nikkei 225

32,397.00

-222.00

-0.68%

Dow Jones

33,963.84

-106.58

-0.31%

FTSE 100 Futures

7,717.00

+24.5

+0.32%

Market Movers

Name	Last	Chg. %	Vol.
BP	525.70	+1.02%	45.26M
CRH	4,341.00	-1.03%	39.92M
HSBC	643.10	+1.10%	35.02M
Shell	2,607.50	+0.44%	9.54M
Unilever	4,116.00	-0.46%	3.60M
Rio Tinto PLC	5,183.00	+0.84%	3.28M
AstraZeneca	11,046.00	+1.47%	2.65M

Name	Last	Chg. %	Vol.
TCS Group Holding PLC	19.50	+510.71%	43.90K
Frontline	194.60	+71.76%	1.94K
Arkle Resources	0.50	+53.85%	9.51M
Physiomics	2.60	+48.57%	15.29M
Saipem	1.49	+37.28%	6.68M
Fusion Antibodies	6.25	+27.55%	3.25M
Cloudbreak Discovery	0.70	+25.00%	17.60M

Name	Last	Chg. %	Vol.
BioGaia B	101.50	-80.31%	8.98K
H Lundbeck B	37.78	-78.25%	71.03K
Atlas Copco B	124.90	-66.94%	37.92K
Tomra Systems	130.45	-62.49%	16.45K
Electrolux B	112.50	-44.30%	166.26K
MTG B	74.90	-28.05%	10.89K
Regtech Open Project	63.25	-24.48%	110.72K

Trending Stocks

Name	Last	Chg. %	Vol.
Avacta Group	129.00	+0.78%	1.67M
Blencowe	4.90	+15.29%	17.72M
Premier African Minerals	0.52	+1.96%	164.92M
Pantheon Resources	31.80	+13.57%	9.09M
Metro Bank	62.50	-3.85%	2.65M

NFXN Comments

low risk now, 3 mill mcap to 328mill yeah ill take that thanks when we get that order in within the next month or so. Take a look at the new presentation, its excellent, shows how much we are worth on first order, and we will get offers by the sound of it. Every faith in Dan, what a man!
0
I think this is one of those shares that fell to its bottom, made progress and now has everyone's interest again. I think it is set to bounce to 1.0 fairly easy then onward and upwards depending on the company. Last raise was December and the presentation is on 22 September so Id expect good investment from there on in . RNS Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that both of the abstracts submitted for presentation at the European Respiratory Society ("ERS") International Congress 2022 in Barcelona on September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted for presentation. NXP002 is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: "We believe NXP002 offers tremendous potential as a novel inhaled treatment for IPF and potentially other fibrosing interstitial lung diseases ("ILDs"). The Company is progressing a pre-clinical programme to demonstrate how its proprietary new form of tranilast can down regulate fibrosis and inflammation following inhalation, whilst avoiding severe side effects, which are key issues in the treatment of IPF and other ILDs. We are therefore delighted that the abstracts describing our initial work have been accepted following peer review. Now, sounds better than good!!!
0
100% Bullish Here
2
Strong buy...so much positive news. due q1
5
- What news? Never came...
  1
Nice to see a positive rns onwards and upwards
2
much more to come. Hold for next waves. sales news and other milestones such as NX0002
0
This could seriously do multiples of current SP.
2

Popular Searches

Please try another search

Nuformix PLC (NFXN)

InvestingPro

Nuformix PLC News

Nuformix PLC Company Profile

Income Statement

Trending Stocks